Russell Investments Group Ltd. Buys 170,842 Shares of Insmed, Inc. $INSM

Key Points

• Russell Investments Group Ltd. increased its holdings in Insmed, Inc. by 129.3% during the first quarter, owning 302,996 shares valued at $23.1 million.
• Insider sales have been notable, with Nicole Schaeffer selling 99,172 shares, representing a 52.59% decrease in her position, while CFO Sara Bonstein sold 58,400 shares, a 44.27% decrease.
• Research analysts have raised their target prices for Insmed, with Wells Fargo lifting its target from $130 to $140 and multiple firms issuing "buy" ratings, indicating strong potential for growth.

Russell Investments Group Ltd. boosted its stake in shares of Insmed, Inc. (NASDAQ:INSM - Free Report) by 129.3% during the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 302,996 shares of the biopharmaceutical company's stock after buying an additional 170,842 shares during the period. Russell Investments Group Ltd. owned approximately 0.17% of Insmed worth $23,116,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of the stock. Vanguard Group Inc. raised its holdings in Insmed by 0.3% during the 1st quarter. Vanguard Group Inc. now owns 18,268,122 shares of the biopharmaceutical company's stock worth $1,393,675,000 after buying an additional 49,149 shares during the period. Darwin Global Management Ltd. raised its holdings in shares of Insmed by 23.5% in the fourth quarter. Darwin Global Management Ltd. now owns 12,960,538 shares of the biopharmaceutical company's stock valued at $894,796,000 after purchasing an additional 2,463,261 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of Insmed by 1.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 12,704,410 shares of the biopharmaceutical company's stock valued at $877,113,000 after purchasing an additional 123,429 shares during the last quarter. Capital International Investors raised its holdings in shares of Insmed by 9.1% in the fourth quarter. Capital International Investors now owns 7,116,997 shares of the biopharmaceutical company's stock valued at $491,357,000 after purchasing an additional 593,206 shares during the last quarter. Finally, Northern Trust Corp raised its holdings in shares of Insmed by 19.9% in the fourth quarter. Northern Trust Corp now owns 1,750,642 shares of the biopharmaceutical company's stock valued at $120,864,000 after purchasing an additional 290,678 shares during the last quarter.

Insmed Stock Up 0.8%

Shares of NASDAQ:INSM traded up $1.08 during midday trading on Thursday, hitting $130.53. The stock had a trading volume of 537,452 shares, compared to its average volume of 2,815,870. Insmed, Inc. has a 12 month low of $60.40 and a 12 month high of $130.33. The company has a quick ratio of 6.33, a current ratio of 6.68 and a debt-to-equity ratio of 0.45. The business's 50-day simple moving average is $106.10 and its 200-day simple moving average is $84.93. The company has a market cap of $27.59 billion, a P/E ratio of -22.86 and a beta of 0.95.

Insmed (NASDAQ:INSM - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($1.70) EPS for the quarter, missing analysts' consensus estimates of ($1.30) by ($0.40). Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The company had revenue of $107.42 million for the quarter, compared to the consensus estimate of $104.06 million. During the same period last year, the firm earned ($1.94) earnings per share. The company's revenue for the quarter was up 18.9% compared to the same quarter last year. Insmed has set its FY 2025 guidance at EPS. On average, sell-side analysts forecast that Insmed, Inc. will post -4.56 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Insmed news, insider Orlov S. Nicole Schaeffer sold 99,172 shares of Insmed stock in a transaction on Wednesday, June 11th. The shares were sold at an average price of $93.42, for a total transaction of $9,264,648.24. Following the completion of the transaction, the insider directly owned 89,407 shares of the company's stock, valued at $8,352,401.94. The trade was a 52.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Sara Bonstein sold 58,400 shares of Insmed stock in a transaction on Monday, July 21st. The stock was sold at an average price of $102.67, for a total transaction of $5,995,928.00. Following the transaction, the chief financial officer directly owned 73,505 shares of the company's stock, valued at approximately $7,546,758.35. This trade represents a 44.27% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 504,694 shares of company stock valued at $48,660,104 over the last ninety days. 3.00% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

INSM has been the topic of a number of recent research reports. Citigroup upgraded shares of Insmed to a "buy" rating in a report on Tuesday, June 10th. William Blair initiated coverage on shares of Insmed in a report on Wednesday. They issued an "outperform" rating on the stock. Truist Financial lifted their price objective on shares of Insmed from $126.00 to $139.00 and gave the company a "buy" rating in a report on Thursday, August 14th. Bank of America lifted their price objective on shares of Insmed from $94.00 to $109.00 and gave the company a "buy" rating in a report on Wednesday, June 11th. Finally, Mizuho lifted their price objective on shares of Insmed from $130.00 to $165.00 and gave the company an "outperform" rating in a report on Wednesday, August 13th. Sixteen analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $132.57.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.